What influences healthcare providers’ prescribing decisions? Results from a national survey

Simani M. Price; Amie C. O'Donoghue; Lou Rizzo; Saloni Sapru; Kathryn J. Aikin

doi:10.1016/j.sapharm.2021.01.012

journal article Oct 01, 2021

What influences healthcare providers’ prescribing decisions? Results from a national survey

Simani M. Price Amie C. O'Donoghue Lou Rizzo Saloni Sapru Kathryn J. Aikin

Research in Social and Administrative Pharmacy Vol. 17 No. 10 pp. 1770-1779 · Elsevier BV

View at Publisher Save 10.1016/j.sapharm.2021.01.012

Topics

No keywords indexed for this article. Browse by subject →

References

54

[1]

Gagnon "The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States" PLoS Med (2008) 10.1371/journal.pmed.0050001

[2]

Austad "Association of marketing interactions with medical trainees' knowledge about evidence-based prescribing: results from a national survey" JAMA Int. Med. (2014) 10.1001/jamainternmed.2014.2202

[3]

Austad "Changing interactions between physician trainees and the pharmaceutical industry: a national survey" J Gen Intern Med (2013) 10.1007/s11606-013-2361-0

[4]

Soyk "Medical student exposure to and attitudes about pharmaceutical companies" Wis Med J (2010)

[5]

Carroll "To what extent do educational interventions impact medical trainees' attitudes and behaviors regarding industry-trainee and industry-physician relationships?" Pediatrics (2007) 10.1542/peds.2007-0363

[6]

Campbell "A national survey of physician-industry relationships" N Engl J Med (2007) 10.1056/nejmsa064508

[7]

Legislature

[8]

Hwong "The effects of public disclosure of industry payments to physicians on patient trust: a randomized experiment" J Gen Intern Med (2017) 10.1007/s11606-017-4122-y

[9]

Grande "Effect of exposure to small pharmaceutical promotional items on treatment preferences" Arch Intern Med (2009) 10.1001/archinternmed.2009.64

[10]

Physicians and the Pharmaceutical Industry

Ashley Wazana

JAMA 2000 10.1001/jama.283.3.373

[11]

DeJong "Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries" JAMA Int. Med. (2016) 10.1001/jamainternmed.2016.2765

[12]

Fleischman "Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study" BMJ (2016) 10.1136/bmj.i4189

[13]

Evans "Residency curricula on physician-pharmaceutical industry interaction: a CERA study" Fam Med (2016)

[14]

Sierles "Changes in medical students' exposure to and attitudes about drug company interactions from 2003 to 2012: a multi-institutional follow-up survey" Acad Med (2015) 10.1097/acm.0000000000000686

[15]

Anderson "Factors associated with physicians' reliance on pharmaceutical sales representatives" Acad Med (2009) 10.1097/acm.0b013e3181ace53a

[16]

Narayanan "Temporal differences in the role of marketing communication in new product categories" J Market Res (2005) 10.1509/jmkr.2005.42.3.278

[17]

Manchanda "Responsiveness of physician prescription behaviour to salesforce effort: an individual level analysis" Market Lett (2004) 10.1023/b:mark.0000047389.93584.09

[18]

Alkhateeb "Characteristics of physicians who frequently see pharmaceutical sales representatives" J Hosp Market Publ Relat (2009) 10.1080/15390940802581374

[19]

Ladd "Under the radar": nurse practitioner prescribers and pharmaceutical industry promotions" Am J Manag Care (2010)

[20]

Crigger "Nurse practitioners' perceptions and participation in pharmaceutical marketing" J Adv Nurs (2009) 10.1111/j.1365-2648.2008.04911.x

[21]

Baker "The role of the medical science liaison in industry" AORN J (2010) 10.1016/j.aorn.2010.01.008

[22]

Othman "Quality of pharmaceutical advertisements in medical journals: a systematic review" PLoS One (2009) 10.1371/journal.pone.0006350

[23]

Fischer "Prescribers and pharmaceutical representatives: why are we still meeting?" J Gen Intern Med (2009) 10.1007/s11606-009-0989-6

[24]

Chressanthis "Determinants of pharmaceutical sales representative access limits to physicians" J Med Mark (2014) 10.1177/1745790415583866

[25]

Jureidini "Clinical trials and drug promotion: selective reporting of study 329" Int J Risk Saf Med (2008) 10.3233/jrs-2008-0426

[26]

Villanueva "Accuracy of pharmaceutical advertisements in medical journals" Lancet (2003) 10.1016/s0140-6736(03)12118-6

[27]

Caudill "The influence of pharmaceutical industry advertising on physician prescribing" J Drug Issues (1992) 10.1177/002204269202200212

[28]

Wick "The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry" Ann Oncol (2007) 10.1093/annonc/mdm402

[29]

Meffert "Key opinion leaders: where they come from and how that affects the drugs you prescribe" Dermatol Ther (2009) 10.1111/j.1529-8019.2009.01240.x

[30]

Sismondo "Key opinion leaders and the corruption of medical knowledge: what the Sunshine Act will and won't cast light on" J Law Med Ethics (2013) 10.1111/jlme.12073

[31]

Dumovic "Marketing masterclass medical science liaisons: a look to the future" Journal of Medical Marketing (2008) 10.1057/jmm.2008.12

[32]

Gupta "An insight into the emerging role of regional medical advisor in the pharmaceutical industry" Perspect Clin Res (2013) 10.4103/2229-3485.115386

[33]

Physicians under the Influence: Social Psychology and Industry Marketing Strategies

Sunita Sah, Adriane Fugh-Berman

Journal of Law, Medicine & Ethics 2013 10.1111/jlme.12076

[34]

Tal "Blinded with science: trivial graphs and formulas increase ad persuasiveness and belief in product efficacy" Publ Understand Sci (2016) 10.1177/0963662514549688

[35]

U.S. Food and Drug Administration. Office of Prescription Drug Promotion (OPDP) Research. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-prescription-drug-promotion-opdp-research.

[36]

O'Donoghue "Awareness of the Food and Drug Administration's Bad Ad program and education regarding pharmaceutical advertising: a national survey of prescribers in ambulatory care settings" J Health Commun (2015) 10.1080/10810730.2015.1018649

[37]

Kasselheim "Physicians' perspectives on FDA approval standards and off-label drug marketing" JAMA Int. Med. (2019) 10.1001/jamainternmed.2018.8121

[38]

Kesselheim "Physicians' knowledge about FDA approval standards and perceptions of the “breakthrough therapy” designation" J Am Med Assoc (2016) 10.1001/jama.2015.16984

[39]

Cohen "Awareness, knowledge, and perceptions of biosimilars among specialty physicians" Adv Ther (2017) 10.1007/s12325-016-0431-5

[40]

Manalo "The current state of dermatologists' familiarity and perspectives of biosimilars for the treatment of psoriasis: a global cross-sectional survey" J Drugs Dermatol JDD (2017)

[41]

Cohen "The importance of countering biosimilar disparagement and misinformation" BioDrugs (2020) 10.1007/s40259-020-00433-y

[42]

Leber "Optimizing use and addressing challenges to uptake of biosimilars" Am J Manag Care (2018)

[43]

Dolan "Opportunities and challenges in biosimilar uptake in oncology" Am J Manag Care (2018)

[44]

Lynn "Separating refusal bias and non‐contact bias: evidence from UK national surveys" J Roy Stat Soc: Series D (The Statistician) (2002)

[45]

Lin "Using survey participants to estimate the impact of nonparticipation" Publ Opin Q (1995) 10.1086/269471

[46]

Durrant "Multilevel modelling of refusal and non-contact in household surveys: evidence from six UK Government surveys" J Roy Stat Soc A (2009) 10.1111/j.1467-985x.2008.00565.x

[47]

The American Association for Public Opinion Research

[48]

Battaglia "Nonprobability sampling" (2008)

[49]

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Yoav Benjamini, Yosef Hochberg

Journal of the Royal Statistical Society Series B:... 1995 10.1111/j.2517-6161.1995.tb02031.x

[50]

Milliken (2009)

Showing 50 of 54 references

Metrics

24

Citations

54

References

Details

Published: Oct 01, 2021
Vol/Issue: 17(10)
Pages: 1770-1779
License: View

Authors

Funding

U.S. Food and Drug Administration Award: HHSF223201510001B

Cite This Article

Simani M. Price, Amie C. O'Donoghue, Lou Rizzo, et al. (2021). What influences healthcare providers’ prescribing decisions? Results from a national survey. Research in Social and Administrative Pharmacy, 17(10), 1770-1779. https://doi.org/10.1016/j.sapharm.2021.01.012

What influences healthcare providers’ prescribing decisions? Results from a national survey

You May Also Like